Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company that...
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a gl...
Progenics develops innovative medicines and other technologies to target and treat...
Progenics develops innovative medicines and oth...
United-Guardian, Inc. ("United") is a diversified company that conducts research, ...
United-Guardian, Inc. ("United") is a diversifi...
Aytu is committed to better health for men and women here at home and worldwide. W...
Aytu is committed to better health for men and ...
Moderna is advancing messenger RNA (mRNA) science to create a new class of transfo...
Moderna is advancing messenger RNA (mRNA) scien...
ArQule is a biopharmaceutical company engaged in the research and development of t...
ArQule is a biopharmaceutical company engaged i...
Benitec is a biotechnology company developing a proprietary therapeutic technology...
Benitec is a biotechnology company developing a...
Join the National Investor Network and get the latest information with your interests in mind.